格隆汇10月9日丨和铂医药-B(02142.HK)公告，10月9日耗资76万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 第 2 頁 共 7 頁 v 1.3.0 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | | ...

Core Viewpoint - The announcement of the Nobel Prize in Physiology or Medicine is expected to stimulate the development of Treg cell therapy and innovative drug research, benefiting companies like HAPO Pharmaceuticals [1] Company Summary - HAPO Pharmaceuticals-B (02142) saw its stock price rise over 8% in early trading, currently up 6.3% at HKD 16.36, with a trading volume of HKD 58.26 million [1] - The company is developing a next-generation antibody HBM4003 targeting the CTLA-4 pathway, which has shown excellent safety characteristics in clinical studies and demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - HAPO's antibody HBM1022, targeting the CCR8 pathway, is considered a highly promising candidate in its pipeline, potentially leading to breakthroughs in tumor immunotherapy [1]

Core Insights - Simply Wall St's report highlights Heptagon Pharmaceuticals as a biotech company with significant growth potential, noting a 243% increase in revenue over the past year, which outpaces the industry growth rate, while its price-to-earnings ratio remains below the average of 52 times for the biotech sector [1] - On October 8, Heptagon Pharmaceuticals' stock surged by 7.08%, closing at HKD 16.48, with a price-to-earnings ratio of approximately 25 times and a total market capitalization of around HKD 14.3 billion [1] - The company focuses on immunological diseases and oncology, leveraging core technological advantages and a differentiated product pipeline through self-development, joint development, and diverse international collaborations [1] Financial Performance - Heptagon Pharmaceuticals reported total revenue of approximately CNY 725 million for the first half of the year, representing a year-on-year increase of 327% [2] - The company's profit reached approximately CNY 523 million, reflecting a year-on-year growth of 51 times [2] - Cash reserves are robust, amounting to approximately CNY 2.291 billion, which is a 92% increase compared to the end of the previous year [2] Investment Activity - The Government of Singapore Investment Corporation (GIC) recently increased its stake in Heptagon Pharmaceuticals by acquiring 40.22 million shares at an average price of HKD 12.7133 per share, totaling approximately HKD 511 million [2] - Following this acquisition, GIC's ownership in Heptagon Pharmaceuticals rose significantly from 1.62% to 6.37%, indicating strong confidence in the company's technological capabilities and commercial prospects [2] - As of October 8, the increase in GIC's stake has resulted in an unrealized gain of nearly 30% based on the closing price [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 ...

Core Viewpoint - The report from Simply Wall St highlights that Heptares Therapeutics has experienced a remarkable revenue increase of 243% over the past year, significantly outpacing the industry average growth of 4.1% [1] Financial Performance - Heptares Therapeutics reported a total revenue of approximately 725 million yuan for the first half of the year, representing a year-on-year growth of 327% [1] - The company's profit reached about 523 million yuan, marking a staggering increase of 51 times compared to the previous year [1] - The company has a price-to-earnings ratio of 23, which is below the biotechnology industry average of 52, indicating substantial future growth potential [1] Funding and Financial Stability - Heptares Therapeutics recently raised 517 million HKD through a share placement and repurchased shares worth 121 million HKD [1] - As of June 2025, the company's shareholders' equity is positive, and it has a free cash flow of 49 million USD, positioning the company for continued financial stability [1] Innovation and Market Position - The company's revenue growth has been significantly supported by the licensing and collaboration of innovative products, which are becoming a regular source of income [1] - Heptares Therapeutics has established a strong global collaboration ecosystem based on its industry-leading Harbour Mice® technology platform and its extended 2.0 version technology platform, positioning itself as a "new infrastructure" in global antibody drug development [1]

Core Insights - The announcement of the Nobel Prize in Physiology or Medicine is expected to ignite a surge in the research and development of Treg cell therapy technologies and innovative drugs [1] Company Summary - Heptares Therapeutics-B (02142) saw its stock price increase by over 8% during trading, with a current price of 16.65 HKD and a trading volume of 62.23 million HKD [1] - The company is developing a next-generation antibody HBM4003 targeting the CTLA-4 pathway, which has shown excellent safety characteristics in clinical studies and has demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - In the CCR8 target area, Heptares Therapeutics has developed the HBM1022 antibody, which is considered a highly promising candidate in its pipeline and may lead to breakthroughs in tumor immunotherapy [1]

Core Viewpoint - The announcement of the Nobel Prize in Physiology or Medicine is expected to ignite a surge in the research and development of Treg cell therapy technologies and innovative drugs [1] Company Summary - HBM4003, a next-generation antibody targeting the CTLA-4 pathway developed by the company, has shown excellent safety characteristics in clinical studies and has demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - The company's antibody HBM1022, targeting the CCR8 pathway, is considered a highly promising candidate in its pipeline, potentially leading to breakthroughs in tumor immunotherapy [1] Industry Summary - The recent Nobel Prize recognition in the field of "peripheral immune tolerance" is likely to stimulate interest and investment in Treg cell therapies and related innovative treatments within the biopharmaceutical industry [1]

Core Insights - The Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking work in the field of peripheral immune tolerance, specifically the discovery of regulatory T cells (Treg) and the identification of the transcription factor Foxp3 as their "identity switch" [1] Group 1: Treg Cell Significance - Treg cells are unique "brake cells" in the immune system that specifically express CD4 molecules, functioning to precisely inhibit the overactivation of other immune cells, thereby preventing autoimmune diseases and regulating inflammatory responses [1] - Key proteins such as CTLA-4 and CCR8 are essential for Treg cells to perform their "immune brake" function, making them critical therapeutic targets in the biopharmaceutical field [1] Group 2: Innovation in Drug Development - Several innovative pharmaceutical companies are accelerating their development of Treg-related therapies, with companies like HBM focusing on the CTLA-4 target [2] - HBM's new generation antibody HBM4003 shows higher affinity for the CTLA-4 molecule, improved tumor tissue penetration, and significantly reduced systemic side effects, demonstrating promising safety and efficacy signals in clinical studies for various cancers [2] - HBM is also developing the HBM1022 antibody targeting CCR8, which effectively identifies and kills CCR8-positive Treg cells, positioning it as a potential breakthrough in tumor immunotherapy [2]

Core Viewpoint - The recent announcement by Trump regarding a 100% tariff on all brand/patent drugs starting in October has led to a strong performance in the pharmaceutical sector, particularly among Chinese innovative drug companies, which are not expected to be significantly impacted by this policy [1][1]. Group 1: Stock Performance - Chinese pharmaceutical stocks have shown strong gains, with Heptares Therapeutics (02142) up 8.2% to HKD 15.71, Zai Lab (09688) up 6.83% to HKD 26.6, Innovent Biologics (09969) up 6.61% to HKD 18.87, and WuXi AppTec (603259) (02359) up 5.37% to HKD 115.7 [1][1]. Group 2: Tariff Impact Analysis - Trump's tariff policy applies only to brand/patent drugs and excludes generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) [1][1]. - According to CMB International, the impact on China's innovative drug industry chain is limited, and there is no need for excessive concern [1][1]. - Most Chinese companies have either established production capacity in the U.S. or outsourced production to local Contract Manufacturing Organizations (CMOs), which mitigates the immediate impact of the tariffs [1][1]. Group 3: Export Dynamics - The majority of Chinese innovative drugs exported are in the form of APIs or raw herbal extracts, which are not affected by the new tariff policy, while the proportion of finished drug exports remains low [1][1]. - The investment timeline for multinational corporations (MNCs) to build factories in the U.S. will take time, leading to limited direct impact on CXO orders in the short term [1][1]. Group 4: Future Catalysts - Upcoming catalysts include the ESMO conference scheduled for mid to late October and the results of the medical insurance negotiations along with the first version of the commercial insurance innovative drug catalog expected to be announced in October to November [1][1].